3篇
您的检索式：作者名="Qingxia Yue"
|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Dynamic response of utility tunnel during the passage of Rayleigh waves显示文摘The modeling methodologies and calculation of dynamic response of underground structure under Rayleigh waves is investigated in this paper. First the free field responses under Rayleigh waves are analyzed and the numerical results agree well with the theoretical results. Then, the approximate Rayleigh waves are put forward based on the preliminary re-search, and Rayleigh wave field is obtained through fast Fourier transform technique. Taking a utility tunnel as an example, its dynamic responses under Rayleigh waves is calculated by ABAQUS. The results demonstrate that bending deformation is the main component of structural deformation and the deformation at the top of the structure is about twice as much as that at bottom of the structure. The effect of soil-structure interface and the buried depth of underground structure are also investi-gated via parameter analysis. For the shallow buried underground structures, Rayleigh waves can be the key factor to control the responses and damage of the structure. | Jie Li Qingxia Yue Jun Chen | 2010 | Earthquake Science2010，23，1： | 10 |
| 2 | Finite element analysis on mechanical behavior of column underpinning joints for building moving 显示文摘 | Yue Qingxia Zhang Xin | 2011 | Advanced Materials Research2011，158，4： | 1 |
| 3 | Paclitaxel and cisplatin with or without cetuximab in metastatic esophageal squamous cell carcinoma:a randomized,multicenter phase II trial显示文摘Lack of effective targeted therapy in metastatic esophageal squamous cell carcinoma(ESCC)underscores the urgent need for identifying new treatment approaches for this challenging disease.We sought to assess the addition of cetuximab to paclitaxel-cisplatin chemotherapy for first-line treatment in patients with metastatic ESCC.In this randomized,multicenter,open-label,phase II clinical trial,patients were randomized to receive paclitaxel-cisplatin(TP)(paclitaxel[175 mg/m^(2) intravenously(i.v.)on day 1 of every 3-week cycle]and cisplatin[75 mg/m^(2) i.v.on day 1 of every 3-week cycle])and TP plus cetuximab(CTP)(cetuximab,400 mg/m^(2) i.v.on day 1 of week 1,followed by 250 mg/m^(2) weekly). | Zhihao Lu Yanqiao Zhang Qingxia Fan Yueyin Pan Da Jiang Ping Lu Jingdong Zhang Xianglin Yuan Jifeng Feng Shujun Yang Wenbin Yue Lin Zhao Yunhua Xu Jinhua Luo Lin Shen | 2022 | The Innovation2022，3，3： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员